IgGenix
Solving allergies with precision antibody engineering
- Headquarters
- San Francisco Bay Area, California
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- iggenix.com
- Total Funding
- $75.0M
- Last Round
- $40.0M Series BFeb 2023
About
IgGenix is a clinical-stage antibody discovery and development company using its proprietary SEQ SIFTER single-cell RNA-sequencing platform to identify and re-engineer rare human IgE antibodies into high-affinity IgG4 therapeutics. Its lead program, IGNX001, targets peanut allergy and has completed Phase 1 enrollment; the pipeline also includes food, environmental, and atopic disease programs.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account